TGCT is a rare disease that is difficult to manage, surgical resection is the primary treatment currently available. To date no disease registry exists and there is little data available detailing the management of patients with diffuse TGCT (d-TGCT), the burden of d-TGCT for patients (including pain, joint stiffness, swelling, reduced mobility and quality of life) or the economic impact of d-TGCT. This study aims to collect data by an observational disease registry involving no intervention to the patient or changes to investigators treatment decisions.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants According to the Management Plan in Patients With Diffuse TGCT (d-TGCT)
Timeframe: Baseline up to end of observation period (approximately 2 years)
Number of Participants According to the Current TGCT Treatment Plan in Patients With Diffuse TGCT (d-TGCT)
Timeframe: Baseline up to end of observation period (approximately 2 years)
Number of Participants Based on Type of Treatment Plan in Patients With Diffuse TGCT (d-TGCT)
Timeframe: Baseline up to end of observation period (approximately 2 years)
Number of Participants Based on Status of Treatment Plan in Patients With Diffuse TGCT (d-TGCT)
Timeframe: Baseline up to end of observation period (approximately 2 years)
Number of Participants Based on Type of Current TGCT Treatment in Patients With Diffuse TGCT (d-TGCT)
Timeframe: Baseline up to end of observation period (approximately 2 years)
Number of Participants Based on Tumor Severity Classification at Baseline Based on MRI in Patients With Diffuse TGCT (d-TGCT)
Timeframe: at Baseline
Number of Cases With Complications Due to Surgery in Patients With Diffuse TGCT (d-TGCT)
Timeframe: at Baseline (prior to any d-TGCT therapy)
Number of Participants With Tumor Recurrence at Baseline in Patients With Diffuse TGCT (d-TGCT)
Timeframe: at Baseline
Time Since Most Recent Tumor Recurrence Until Baseline in Patients With Diffuse TGCT (d-TGCT)
Timeframe: at Baseline
Time From Baseline to First Tumor Recurrence in Patients With Diffuse TGCT (d-TGCT)
Timeframe: Baseline up to end of observation period (approximately 2 years)
Mean Brief Pain Inventory (BPI) Pain Severity and Interference Score From Baseline Through 24 Months
Timeframe: Baseline up to end of observation period (approximately 2 years)
Mean Worst Stiffness Score From Baseline Through 24 Months
Timeframe: Baseline up to end of observation period (approximately 2 years)
Mean PROMIS Physical Function Score From Baseline Through 24 Months
Timeframe: Baseline up to end of observation period (approximately 2 years)